Want to join the conversation?
$BIIB, global leader in the multiple sclerosis market, reported 4Q15 sales jump of 7.5% YoverY to $2.84Bil, driven by higher revenue from Tecfidera, Plegridy and Eloctate. For the quarter, net income attributable to $BIIB fell 5.8% to $831.6MM, or $3.77 per diluted share, compared with $883.5MM, or $3.74 per diluted share, a year ago.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)